SAB Biotherapeutics (SABS)
Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.
Something off on this page? Send us feedback.
Develops SAB-142, an investigational fully human anti-thymocyte globulin for newly diagnosed autoimmune diabetes, using a transchromosomic-cattle platform to generate multi-specific polyclonal antibodies. Its development-stage model centers on clinical advancement and financing rather than commercial product sales.
Develops SAB-142, an investigational fully human anti-thymocyte globulin for newly diagnosed autoimmune diabetes. The therapy uses multi-specific polyclonal antibodies intended to modulate immune cells involved in pancreatic beta-cell destruction.
Runs the Tc Bovine/DiversitAb platform from a Miami Beach corporate office and a South Dakota research and manufacturing base, combining transchromosomic cattle, plasma collection, process development, and clinical-scale cGMP operations. Clinical activity extends across the United States, Australia, and New Zealand, with manufacturing support contracted in Canada.
Depends on the SAFEGUARD trial, regulatory review, animal-herd supply, specialized manufacturing, and continued financing. Has no approved product, commercial sales, marketing, or distribution operation.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 24, 2026 | Barclays | Initiate | Rating: —Target: — | Target: $13 |
| May 20, 2026 | Jefferies | Target | Target: — | Target: $11 |
| May 12, 2026 | H.C. Wainwright | Target | Target: $6 | Target: $10 |
| Jan 7, 2026 | UBS | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $102.6M · Total debt $5.1M · Total assets $238.2M · Shareholders' equity $214.8M
- Revenue
- $0
- Operating income
- −$23.4M
- Net income
- −$22.5M
No dividends on record.
| Institutions | 75.29% | 68.50M shares | |
|---|---|---|---|
| 92 holders · as of Jun 30, 2026 | |||
| Insiders | 0.05% | 41.9K shares | |
| 1 holder · as of Sep 18, 2026 | |||
| Other | 24.66% | 22.44M shares | |
| remainder | |||
90.99M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Caligan Partners LPInstitution | 8.76% | 7.97M | as of Jun 30, 2026 |
Vivo Capital, LLCInstitution | 8.02% | 7.30M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 7.28% | 6.63M | as of Jun 30, 2026 |
Adage Capital Partners GP, L.L.C.Institution | 7.04% | 6.41M | as of Jun 30, 2026 |
Adage Capital Management, L.P.Institution | 7.04% | 6.41M | filed Aug 12, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Sanofi (ADR)
Approved Tzield and Thymoglobulin lead immune therapy and ATG overlap.
- Biomea Fusion
Icovamenib pursues beta-cell restoration in the same T1D population.
- Pfizer
Atgam is an established animal-derived ATG benchmark.
- vTv Therapeutics
Cadisegliatin is a Phase 3 oral adjunct for adult T1D.
- Sana Biotechnology
SC451 seeks insulin independence through immune-evasive islet replacement.
- Century Therapeutics
CNTY-813 targets a functional cure with iPSC-derived islets.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics | $3.33 | −4.86% | $318.5M | — | — | — | — |
| Sanofi (ADR) | $41.49 | −2.40% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Biomea Fusion | $1.39 | −18.31% | $122.9M | — | — | — | — |
| Pfizer | $28.18 | +0.88% | $159.19B | 36.9 | 10.1 | 2.5 | +2.6% |
| vTv Therapeutics | $30.51 | −1.91% | $81.4M | — | — | 2.2 | — |
| Sana Biotechnology | $3.05 | −8.28% | $926.7M | — | — | — | — |
| Century Therapeutics | $1.82 | −3.97% | $163.6M | — | — | — | — |
| Median | 56.5 | 10.1 | 2.2 | +6.9% |